Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's revenue and earnings dropped off a cliff last year. However, the biotech is close to launching a new product.

1 Stock Down 43% to Buy and Hold for 10 Years

Pfizer

Pfizer is completing its biggest string of product launches ever, which should spur a new era of growth. Moderna expects to soon have a new RSV vaccine on the market, with other products to follow.

Better Bull Market Buy: Pfizer vs. Moderna

Moderna went from being a stock market winner, soaring more than 400%, to a losing stock in recent times. Investors have worried about coronavirus vaccine declines and the biotech company's future revenue picture.

3 Things That Could Help 2023 Loser-Stock Moderna Roar Higher in 2024

Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Asensus Surgical

Editas Medicine

Hologic

Illumina

Johnson & Johnson

Verve Therapeutics

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

Lumen Technologies

Plug Power

Plug Power's financials are in horrible shape, and a lack of cash is a big concern for investors. Moderna's reliance on COVID and flu revenue could limit any growth it's able to generate ahead.

3 Struggling Businesses Investors Shouldn't Gamble on This Year

Amgen

Centene

Cencora Inc

Catalent

Gilead Sciences

Medtronic

Merck

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Amylyx Pharmaceuticals

Boston Scientific

CRISPR Therapeutics

Globus Medical

iRhythm Technologies

Teladoc

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

7 Healthcare Stocks Taking Medicine to the Next Level

Enphase Energy

Tesla

Owning powerhouse stocks can add significant value to your portfolio. Megatrends are those that are shaping or will shape society in significant ways.

3 Megatrend Stocks that Will Revolutionize Your Portfolio

Apple

Chewy

Alphabet

A well-thought-out portfolio could help you win this year and over time. It's crucial to diversify your investments and invest for the long term.

The Best Places to Invest $100,000 in 2024

Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands Saint-Cloud, 10 January 2024 – Elis, the global leader in circular services at work, today announces the signing of an agreement to acquire 100% of Moderna Holding BV (« Moderna ») in the Netherlands. The closing of the transaction is expected to occur before the end of Q1 2024, subject to the standard regulatory reviews.

Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands

PayPal

Today, identifying investments with promising growth potential is a quest every investor undertakes. Within the loud noises of the stock market, three standout companies are making waves.

Your Path to Wealth: 3 Stocks Predicted to Double Your Investment by 2025

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Fortinet

Palo Alto Networks

Paycom Software

Royal Caribbean Cruises

7 S&P 500 Stocks to Buy to Keep the Bull Market Running

Moderna, Inc. (MRNA) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Bayer AG

Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday.  Founded in 2018 by scientists at UC Berkeley, Metagenomi's revenue to date has come from a trio of collaborations, including one with backer Moderna.

Moderna, Bayer-backed genetic therapies company files for IPO

Covid-19 vaccine maker Moderna said 2023 product sales hit $6.7 billion, above the company's guidance, but down more than 60% from 2022.

Moderna Stock Is Rising. Sales Fell a Bit Less Than Expected in 2023.

Moderna Inc.'s stock MRNA, +2.26% was up by 1.2% after the drug maker said it sold $6.7 billion of products in 2023. Analyst expected the company to sell $6.35 billion in products in 2023.

Moderna's stock rises on 2023 product sales of $6.7B

Moderna on Monday reported preliminary 2023 sales of $6.7 billion for its COVID vaccine, surpassing the lower end of its full-year forecast, while reiterating its goal of returning to sales growth in 2025.

Moderna's 2023 prelim COVID vaccine sales meet target

Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.

Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast

Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022 Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment Company highlights nine late-stage programs with anticipated milestones in 2024 and 2025 CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's pipeline of transformative mRNA medicines. Moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference

Dollar General

When a stock declines, it could be an opportunity or a danger sign. The four worst performers in the S&P 500 in 2023 spanned completely different sectors.

Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?

Moderna's mRNA-1083 vaccine, targeting COVID-19 and flu, in Phase 3, reflects innovation in combination vaccinations. Despite recent financial losses, Moderna maintains strong liquidity with $12.8 billion in cash and investments; however, faces operational cost challenges. Market sentiment is mixed with underperformance in stock and high institutional ownership, amidst competition from Pfizer's similar vaccine.

Moderna's Flu/COVID Vaccine Prospects Are Undervalued By The Market

Allstate

Incyte

Eli Lilly

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

7 Stocks Are Taking Off Already — And The Year Just Started

Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.

News for Moderna Stock (MRNA)